1. Pink Sheet

EMA Discusses Fatal Events That Prompted Pfizer To Pull Oxbryta From Global Markets

The CHMP is holding an extraordinary meeting to discuss the emerging data for the sickle cell disease drug

 
• By Neena Brizmohun

The company’s decision to withdraw the drug was based on “the totality of clinical data that now indicates the overall benefit of Oxbryta no longer outweighs the risk in the approved sickle cell patient population.”

Oxbryta was the first medicine approved that directly inhibits sickle hemoglobin polymerization, the root cause of SCD • Source: Shutterstock

The European Medicines Agency is holding a meeting today to discuss the emerging clinical data and deaths that have caused Pfizer to voluntarily withdrawing its sickle cell disease (SCD) treatment, Oxbryta (voxelotor), from the 35 countries in which it is approved for marketing.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from EU CHMP

More from Pink Sheet

Pink Sheet Podcast: More US FDA Departures, Makary On Combined AE Database, ‘Conditional’ Approval

 
• By Derrick Gingery, Sarah Karlin-Smith, and Sue Sutter

Pink Sheet reporter and editors discuss the most recent senior staff departures at the FDA and their impact on the agency, as well as Commissioner Martin Makary’s plans for a new approval pathway and a combined adverse event database as outlined in an interview with a podcast host.

Vertex’s Alyftrek For CF Among Six Orphans On Track For Pan-EU Approval

 
• By Eliza Slawther

The European Medicines Agency has recommended 16 drugs for EU-wide approval, including Vertex’s cystic fibrosis drug Alyftrek and five other orphans.

Quotable: Top Experts On Policy Hot Topics

 
• By Anabel Costa-Ferreira

The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.